Faron, etusivu

releases and publications

Faron Pharmaceuticals presents Phase II data from BEXMAB Study at ASCO 2025

Faron announces publication of full Phase I BEXMAB study data in Lancet Haematology

Faron Pharmaceuticals Ltd: Issue of Treasury Shares to the Company

Regulatory

Faron’s Bexmarilimab demonstrates immune-activating and drug-sensitizing potential in myeloid malignancies

Faron announces new data that highlight patient populations with cancer that are most likely to benefit from first-in-class immunotherapy bexmarilimab

Faron Appoints Ralph Hughes as Chief Business Officer (CBO)

Regulatory

Faron Announces Acceptance of Bexmarilimab Data for Oral Presentation at EHA 2025 Congress

Faron Pharmaceuticals Ltd: Grant of Options

Insider Transaction Regulatory

Faron Pharmaceuticals presents promising Phase 1/2 data from BEXMAB Study at MDS 2025 plenary session

Faron announces acceptance of bexmarilimab Phase II data for oral presentation at ASCO 2025

Next
Back to top